Initial data using transcranial ultrasound in combination with tissue Plasminogen Activator (tPA) for sonothrombolysis in stroke are promising. However, absorption and defocusing of the ultrasound beam occur during transskull insonation, limiting the efficiency of this approach to high extent. The purpose of this in vitro study was to investigate whether transcranial sonothrombolysis can be achieved using High Intensity Focused Ultrasound (HIFU) without the use of tPA. The use of transskull HIFU for immediate clot lysis without the need of further drugs and disregarding individual skull bone characteristics is feasible in vitro. Stroke is the second most common cause of death worldwide. 800,000 U.S. citizens suffer from stroke every year. Tissue Plasminogen Activator (tPA) is the only FDA approved drug for stroke treatment. Due to the restricted time window and various exclusion criteria less than 3% of all stroke victims are currently receiving tPA therapy. Less than 40% of stroke patients treated with tPA demonstrate good clinical recovery on the long term.
Last date updated on November, 2020